Edoxaban Use in Nonvalvular Atrial Fibrillation With Valvular Heart DiseaseInsights from ENGAGE AF-TIMI 48

被引：1
作者：
Owens, Ryan E. [1 ]
Kabra, Rajesh [2 ]
Oliphant, Carrie S. [3 ]
机构：
[1] Univ Oklahoma, Coll Pharm, Dept Pharm Clin & Adm Sci, Oklahoma City, OK 73106 USA
[2] Univ Tennessee, Ctr Hlth Sci, Dept Internal Med, Div Cardiol, Memphis, TN 38163 USA
[3] Univ Tennessee, Coll Pharm, Methodist Univ Hosp, Dept Clin Pharm, Memphis, TN USA
来源：
CLINICAL CARDIOLOGY | 2017年 / 40卷 / 08期
关键词：
Valvular heart disease; Arrhythmia; all; management; WARFARIN;
D O I：
10.1002/clc.22690
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：612 / 613
页数：2
相关论文
共 50 条
  • [41] Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial
    Yin, Ophelia Q. P.
    Antman, Elliott M.
    Braunwald, Eugene
    Mercuri, Michele F.
    Miller, Raymond
    Morrow, David
    Ruff, Christian T.
    Truitt, Kenneth
    Weitz, Jeffrey I.
    Giugliano, Robert P.
    CIRCULATION, 2018, 138 (18) : 1963 - 1973
  • [42] Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation The ENGAGE AF-TIMI 48 Trial
    Ruff, Christian T.
    Giugliano, Robert P.
    Braunwald, Eugene
    Mercuri, Michele
    Curt, Valentin
    Betcher, Joshua
    Grip, Laura
    Cange, Abby L.
    Crompton, Andrea E.
    Murphy, Sabina A.
    Deenadayalu, Naveen
    Antman, Elliott M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (06) : 576 - 584
  • [43] Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF-TIMI 48 Trial Setting a New Standard
    Eikelboom, John W.
    Vanassche, Thomas
    Connolly, Stuart J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (06) : 585 - 587
  • [44] External validation of AF-BLEED for predicting major bleeding and for tailoring NOAC dose in AF patients: A post hoc analysis in the ENGAGE AF-TIMI 48
    Chu, G.
    Valerio, L.
    Barco, S.
    Huisman, M. V.
    Konstantinides, S. V.
    Klok, F. A.
    THROMBOSIS RESEARCH, 2023, 229 : 225 - 231
  • [45] Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
    Nabeta, Takeru
    Kida, Keisuke
    Ishida, Miwa
    Shiono, Takaaki
    Suzuki, Norio
    Doi, Shunichi
    Tsukahara, Maya
    Ohta, Yuki
    Kimura, Tetsuya
    Yamaguchi, Keita
    Takita, Atsushi
    Matsumoto, Naoki
    Akashi, Yoshihiro J.
    Ako, Junya
    Inomata, Takayuki
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1061 - 1071
  • [46] Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
    Di Biase, Luigi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (02):
  • [47] Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial
    Fagundes, Antonio
    Ruff, Christian T.
    Morrow, David A.
    Murphy, Sabina A.
    Palazzolo, Michael G.
    Chen, Cathy Z.
    Jarolim, Petr
    Antman, Elliott M.
    Braunwald, Eugene
    Giugliano, Robert P.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 386 : 118 - 124
  • [48] Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation Insights From ROCKET AF
    van Diepen, Sean
    Hellkamp, Anne S.
    Patel, Manesh R.
    Becker, Richard C.
    Breithardt, Guenter
    Hacke, Werner
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Nessel, Christopher C.
    Singer, Daniel E.
    Berkowitz, Scott D.
    Califf, Robert M.
    Fox, Keith A. A.
    Mahaffey, Kenneth W.
    CIRCULATION-HEART FAILURE, 2013, 6 (04) : 740 - 747
  • [49] Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study
    Yamashita, Takeshi
    Igawa, Yoshiyuki
    Fukuzawa, Masayuki
    Hayashi, Takuya
    Hennig, Stefanie
    Okumura, Ken
    THROMBOSIS AND HAEMOSTASIS, 2024, 124 (09) : 874 - 882
  • [50] Long-term visit-to-visit blood pressure variability and risk of cardiovascular and bleeding events: insights from the ENGAGE AF-TIMI 48 trial
    Proietti, Riccardo
    Palazzolo, Michael Gerard
    Ruff, Christian T.
    Lip, Gregory Y. H.
    Giugliano, Robert P.
    HYPERTENSION RESEARCH, 2025, : 1613 - 1618
12345